Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-52411623EnglishN2024December10Healthcare Prevalence of Abnormal Pap Smears at Prince Sultan Military Medical City in Riyadh, Saudi Arabia from 2012 to 2021: A Retrospective Study     English0105Abdullah Bandar AlmutiriEnglish Luluh B. AlBehlalEnglish Rawan Abdullah O. AlshammariEnglish Abdullatif Ahmed AlzahraniEnglish Fadhel Zaben AlotaibiEnglish Introduction: Cancer is a significant global public health concern that demands immediate attention as it affects populations worldwide. Among cancers affecting women, cervical cancer stands out as the fourth most common. Remarkably, it is worth noting that around 90% of these deaths occurred in countries with low or middle incomes. These countries face challenges such as limited access to public health services and the inadequate implementation of screening and treatment measures for this disease. In Saudi Arabia, a country with a population of 10.7 million, women aged 15 years and older are at risk of developing cervical cancer. Aim/Objectives: In this present study, the prevalence of abnormal Pap smears and their quality metrics at the Prince Sultan Military Medical City were analyzed. Additionally, the study sought to shade light on the evolutionary trend of this clinical technique for cervical screening in Riyadh and probably serve as cohort finding for the Saudi population. Methodology: A retrospective analysis was carried out using the medical result sheets from medical analyses conducted between 2010 and 2021, at the Prince Sultan Military Medical City in Saudi Arabia. The focus was on smears, cervical cancer, Human papillomavirus (HPV), and atypical glandular cells. Results: The study examined Pap smear data, including both conventional and liquid-based cytology (LBC), for a total of 27,319 collected between 2010 and 2021.Out of the 27,319 pap smears, 2.93% (801) were classified as abnormal, with 3.18% (869) been considered unsatisfactory (UNSAT) for diagnostic. Conclusion: We recorded 1.72 ratio for atypical squamous cell and squamous intraepithelial cell, as with 0.98% prevalence in abnormal pap smears. We observed a fluctuating, relatively stable and a decreasing frequency of atypical glandular cells, respectively before the onset, during, and after the Covid-19 pandemic. We believe these variations in frequencies are due to different factors. EnglishAbnormal pap, cervical cancer, Saudi Arabia, Human Papillomavirus, immediate attention, Covid-19 pandemichttp://ijcrr.com/abstract.php?article_id=4830http://ijcrr.com/article_html.php?did=4830 1. Stefan DC, Dangou JM, Barango P, Mahamadou ID, Kapambwe S. The World Health Organization targets for cervical cancer control by 2030: a baseline assessment in six African countriespart I. Ecancermedical science. 2022; 16:1453. 2. World Health Organization (WHO). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem [Internet]. Geneva: WHO; 2020 [cited 2024 Oct 23]. Available from: https://www.who.int/publications/i/item/9789240014107. 3. ICO/IARC Information Centre on HPV and Cancer. Saudi Arabia [Internet]. 2023 Mar 10 [cited 2024 Oct 23]. Available from: https://hpvcentre.net/statistics/reports/SAU_FS.pdf. 4. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003 ;16(1) :1–17. 5. Zhong H, Pan W, Chen B, Gu J, Liang Y, Sun G, et al. A realworld, cross-sectional, and longitudinal study on high-risk human papillomavirus genotype distribution in 31,942 women in Dongguan, China. Front Public Health. 2024; 12:1409030. 6. Centers for Disease Control and Prevention (CDC). What are the risk factors for cervical cancer? [Internet]. CDC; 2023 [cited 2024 Oct 23]. Available from:https://www.cdc.gov/cancer/cervical/basic_info/risk_factors.htm. 7. National Cancer Institute. Cervical cancer screening [Internet]. 2023 [cited 2024 Oct 23]. Available from: https://www.cancer. gov/types/cervical/screening. 8. Mufti ST, Altaf FJ. Changing pattern of epithelial cell abnormalities using revised Bethesda system. Iran J Basic Med Sci. 2014;17(10):779–84. 9. Al-Kadri HM, Kamal M, Bamuhair SS, Omair AA, Bamefleh HS. Prevalence and characteristics of abnormal Papanicolaou smear in Central Saudi Arabia. Saudi Med J. 2015;36(1):117–22. 10. Andijany AA, Abdulhafeez DA, Fadag RB, Al Harbi AM, Alsahafi RA, Bin Abbas ES, et al. Prevalence of abnormal pap smears in the western region of Saudi Arabia from 2010 to 2022. CytoJournal. 2023;20(44). 11. Nasser H, AlAyyaf M, Atallah A, Aminulislam M, Rizwan L, Aodah A, et al. Eleven-year review of data on Pap smears in Saudi Arabia: We need more focus on glandular abnormalities! Ann Saudi Med. 2017;37(4):265–71 12. Alissa NA. Knowledge and intentions regarding the Pap smear test among Saudi Arabian women. PLoS One. 2021;16(6): e0253850. 13. AlBabtain FA, Hussain AN, Alsoghayer SA, Alwahbi OA, Almohaisen N, Alkhenizan AH. The yield of pap smears and its characteristics in a community based setting in Saudi Arabia. Saudi Med J. 2020;41(6):661–5. 14. Alahmadi M, Mansour S, Martin D, Atkinson PM. An improved index for urban population distribution mapping based on nighttime lights (DMSP-OLS) data: An experiment in Riyadh Province, Saudi Arabia. Remote Sens. 2021;13(6). 15. Abbas M, De Jonge J, Bettendorf O. Distribution and incidence of atypical glandular lesions in cervical cytology focusing on the association with high-risk human papillomavirus subtypes. Oncol Lett. 2022;25(1):6. 16. Graue R, Lönnberg S, Skare GB, Sæther SMM, Bjørge T. Atypical glandular lesions of the cervix and risk of cervical cancer. Acta Obstet Gynecol Scand. 2020; 99:582–90. 17. Kultalahti H, Heinävaara S, Sarkeala T, Pankakoski M. Effect of test history at ages 50-64 on later cervical cancer risk: A population-based case-control study. Cancer Res Commun. 2023;3(9):1823–9. 18. Zhu B, Yu H, Ni P, Chen X, Zhang J, Wang D. A population-based cross-sectional study on the situation of cervical cancer screening in Liaoning, China. BMC Womens Health. 2023;23(1):144. 19. Lu H, He H, Qin J, Chen M, Liu Q, Li M, et al. Populations at high risk of cervical cancer in Guangxi Province: Findings from two screening projects in a minority area of South China. J Med Screen. 2022;29(1):44–52. 20. Kengsakul M, Manchana T. Coexisting cancers with atypical glandular abnormalities by liquid-based cytology: A retrospective study in tertiary hospital in a high cervical cancer incident country. Taiwan J Obstet Gynecol. 2020;59(5):665–8. 21. Ndifon CO, Al-Eyd G. Atypical Squamous Cells of Undetermined Significance. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. [Updated 2023 Apr 24; cited 2024 Oct 23]. Available from: https://www.ncbi.nlm.nih. gov/books/NBK557739/. 22. Wang YY, Kong LH, Liu Y, Wang S, Fan QB, Zhu L, et al. Retrospective analysis of cervical cancer and precancerous lesions in patients with atypical squamous cells of undetermined significance in China. Medicine (Baltimore). 2019;98(49): e18239. 23. Mello V, Sundstrom RK. Cervical intraepithelial neoplasia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. [Updated 2023 Apr 24; cited 2024 Oct 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544371/. 24. Yousif HM, Albasri AM, Alshanqite MM, Missawi HM. Histopathological patterns and characteristics of abnormal cervical smear in Madinah Region of Saudi Arabia. Asian Pac J Cancer Prev. 2019;20(5):1303–7. 25. Wentzensen N, Clarke MA, Perkins RB. Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities. Prev Med. 2021; 151:106596. 26. Balan L, Secosan C, Sorop VB, Pirtea M, Cimpean AM, Chiriac D, et al. Impact of SARS-CoV-2 pandemic on the diagnosis of cervical cancer and precursor lesions—a single-center retrospective study. Medicina. 2024;60(6):60909.

Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-52411623EnglishN2024December10Healthcare In Silico Exploration of the Potential of Drugs to Cure Obesity from the Natural Product Atlas Investigated using Computer-Aided Drug Design English0612Abdulaziz AlzahraniEnglish Introduction: Obesity is a result of a trifecta of poor diet. Medication for obesity falls into five categories. However, due to their severe adverse effects and low efficacy, existing pharmaceutical therapies are only marginally useful. Therefore, the purpose of this research is to identify natural substances that can be used to prevent and treat obesity and associated diseases. Methods: The 3D structure of pancreatic lipase (PDB ID: pancreatic lipase-colipase) was obtained from the protein data repository with a precision of 2.46. The file, in.pdb format, belongs to the Protein Data Bank. Natural chemicals, was obtained from PubChem. Pharmit software was used to generate the pharmacophore model. The co-crystallized structure served as the foundation for the pharmacophore model. Virtual screening is a drug discovery process that looks for structures with the best likelihood of binding to a therapeutic target. BioVIA Discovery Studio was utilized to identify two-dimensional interactions, whereas PyMOL was utilized to generate intricate receptor and ligand files. We analyze the ADMET properties of the chosen compounds using QikProp. We simulate molecular dynamics for 100 nanoseconds using Desmond software. Results: The Natural Product Atlas database for substances was similar to the properties of the pharmacophore model. Using the PubChem data source, 33372 chemicals were assembled into a library. Sorting 1005 identified hits by their pharmacophore-fit RMSD score resulted in the selection of the top 20 compounds from pharmacophore-based virtual screening. QikProp filtered ADMET properties. Lastly, QPlogKhsa estimated the binding to human serum albumin and provided a range of 1.5 to 1.5. Two medications, NPA002198 and NPA030453, were shown to be the most effective compounds against pancreatic lipase-colipase after lead discovery. Eigenvalues (36.4-76.4% and 25.2-69.9%). The percentage of secondary structural components in pancreatic lipase-colipase-NPA030453 was calculated to be 42.44 percent, with helical and strand rates of 16.17% and 26.26%, respectively. Hydrogen bonds were the most significant receptor-ligand interactions discovered by MD. GLY_76, PHE_77, ILE_78, ASP_79, SER_152, and PHE_215 were the most important hydrogen bonding sites in the pancreatic lipase-colipase-NPA002198 complex. Conclusion: The study found the Natural Product Atlas-approved drugs NPA002198 and NPA030453, which suppressed pancreatic lipase-colipase function. Virtual screening, docking analysis, and pharmacophore modeling was used to identify compounds with the lowest binding affinities to the target protein. We concluded that these compounds might serve as a lead chemical in the development of anti-obesity medicines. These results will benefit science by allowing researchers to develop new pharmaceuticals that can more effectively treat overweight. EnglishObesity, Pancreatic lipase, Natural chemicals, Pharmacophore modeling, Compoundshttp://ijcrr.com/abstract.php?article_id=4831http://ijcrr.com/article_html.php?did=4831 1. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can j Cardiol[Internet].2015;31(2):177–83.Availablefrom: https://www.ncbi.nlm.nih.gov/pubmed/25661552. 2. Rahmouni K. Obesity-Associated Hypertension. Hypertension. 2014 Aug;64(2):215–21. 3. Mittendorfer B, Peterson LR. Cardiovascular consequences of obesity and targets for treatment. Drug Discov. Today: Therapeutic Strategies. 2008 Mar;5(1):53–61. 4. Gersh BJ. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Yearbook of Cardiology. 2012 Jan;2012:252–4. 5. Kim KB, Shin YA. Obese and Overweight Males. J Obes Metab  Syndr. 2020 Mar 9; 6. WHO | Global Health Observatory (GHO) data [Internet]. apps. who.int. Available from: https://apps.who.int/gho/data/motd. html 7. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat. Med. 2004 Mar 31;10(4):355–61 8. Bhurosy T, Jeewon R. Overweight and Obesity Epidemic in Developing Countries: A Problem with Diet, Physical Activity, or Socioeconomic Status? Sci. World J. [Internet]. 2014;2014:1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4212551/ 9. Fall T, Ingelsson E. Genome-wide association studies of obesity and metabolic syndrome. Mol. Cell. Endocrinol. 2014 Jan;382(1):740–57. 10. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat. Rev. Genet [Internet]. 2021 Sep 23;23(23):1–14. Available from: https://www.nature.com/articles/s41576-021-00414-z 11. Oh TJ. The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. J. Obes. Metab. Syndr. 2019 Sep 30;28(3):158–66. 12. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols:food sources and bioavailability. Am. J. Clin. Nutr. 2004 May 1;79(5):727–47. 13. Godos J, Vitale M, Micek A, Ray S, Martini D, Del Rio D, et al. Dietary Polyphenol Intake, Blood Pressure, and Hypertension: A Systematic Review and Meta-Analysis of Observational Studies. Antioxidants (Basel, Switzerland) [Internet]. 2019 May 31 [cited 2020 Jul 18];8(6). Available from: https://pubmed.ncbi. nlm.nih.gov/31159186/ 14. Konstantinidi M, Koutelidakis AE. Functional Foods and Bioactive Compounds: A Review of Its Possible Role on Weight Management and Obesity’s Metabolic Consequences. J. Med [Internet]. 2019 Sep 9;6(3). Available from: https://www.ncbi. nlm.nih.gov/pmc/articles/PMC6789755/ 15. Wang T, Li Q, Bi K. Bioactive flavonoids in medicinal plants: Structure, activity and biological fate. Asian J Pharm Sci. 2018 Jan 1;13(1):12–23. 16. Bourne Y, Martinez C, Kerfelec B, Lombardo D, Chapus C, Cambillau C. Horse Pancreatic Lipase. J Mol Biol. 1994 May;238(5):709–32 17. Lee EM, Lee SS, Chung BY, Cho JY, Lee IC, Ahn SR, et al. Pancreatic Lipase Inhibition by C-Glycosidic Flavones Isolated from Eremochloa ophiuroides. Molecules. 2010 Nov 16;15(11):8251–9. 18. Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov. Today. 2007 Oct;12(19-20):879–89. 19. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. J. Pharmacother [Internet]. 2000 [cited 2019 Nov 5];20(3):270–9. Available from: https:// www.ncbi.nlm.nih.gov/pubmed/10730683 20. Huo PC, Hu Q, Shu S, Zhou QH, He RJ, Hou J, et al. Design, synthesis and biological evaluation of novel chalcone-like compounds as potent and reversible pancreatic lipase inhibitors. Bioorg. Med. Chem.. 2021 Jan;29:115853. 21. Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des [Internet]. 2013 Mar [cited 2019 Jun 26];27(3):221– 34. Available from: https://link.springer.com/article/10.1007%2 Fs10822-013-9644-8 22. Iqbal MN, Rasheed MA, Awais M, Chammam W, Kanwal S, Khan SU, et al. BMT: Bioinformatics mini toolbox for comprehensive DNA and protein analysis. Genomics [Internet]. 2020 Nov 1 [cited 2022 Nov 7];112(6):4561–6. Available from: https://www.sciencedirect.com/science/article/pii/ S0888754320309782 23. Berman HM. The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235–42. 24. Veeramachaneni GK, kodamala KR, Chalasani LM, J S B, Talluri VR. High-throughput virtual screening with e-pharmacophore and molecular simulations study in the designing of pancreatic lipase inhibitors. Drug Des. Devel. Ther. 2015 Aug;4397. 25. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen M, et al. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Protein Sci. 2007 Nov;50(1):2.9.1–31. 26. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis.1997;18(15):2714–23 27. Ho BK, Brasseur R. The Ramachandran plots of glycine and pre-proline. BMC Struct. Biol [Internet]. 2005;5(1):14. Available from: https://bmcstructbiol.biomedcentral.com/articles/ 10.1186/1472-6807-5-14 28. Tian W, Chen C, Liang J. CASTp 3.0: Computed Atlas of Surface Topography of Proteins and Beyond. Biophys J. 2018 Feb;114(3):50a 29. van Santen JA, Jacob G, Singh AL, Aniebok V, Balunas MJ, Bunsko D, et al. The Natural Products Atlas: An Open Access Knowledge Base for Microbial Natural Products Discovery. ACS Cent. Sci. 2019 Nov 14;5(11):1824–33 30. Sunseri J, Koes DR. Pharmit: interactive exploration of chemical space. Nucleic Acids Res. 2016 Apr 19;44(W1):W442–8. 31. Trott O, Olson AJ. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring function, Efficient optimization, and Multithreading. J Comput Chem. 2009;31(2). 32. Mura C, McCrimmon CM, Vertrees J, Sawaya MR. An Introduction to Biomolecular Graphics. PLoS Comput. Biol [Internet]. 2010 Aug 26;6(8):e1000918. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928806/ 33. Systèmes D. Free Download: BIOVIA Discovery Studio Visualizer [Internet]. Dassault Systèmes. 2020. Available from: https:// discover.3ds.com/discovery-studio-visualizer-download 34. Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. admet- SAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties. J Chem Inf Model. 2012 Nov;52(11):3099–105. 35. Bowers KJ, Sacerdoti FD, Salmon JK, Shan Y, Shaw DE, Chow E, et al. Molecular dynamics---Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 2006 ACM/IEEE conference on Supercomputing - SC ’06. 2006; 36. Ferreira L, dos Santos R, Oliva G, Andricopulo A. Molecular Docking and Structure-Based Drug Design Strategies. Molecules. 2015 Jul 22;20(7):13384–421. 37. Hildebrand PW, Rose AS, Tiemann JKS. Bringing Molecular Dynamics Simulation Data into View. Trends Biochem. Sci [Internet]. 2019 Nov 1 [cited 2023 Feb 13];44(11):902–13. Available from: https://www.sciencedirect.com/science/article/pii/ S0968000419301379 38. Rasheed MA, Iqbal MN, Saddick S, Ali I, Khan FS, Kanwal S, et al. Identification of Lead Compounds against Scm (fms10) in Enterococcus faecium Using Computer Aided Drug Designing. Life. 2021 Jan 21;11(2):77. 39. Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W. Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. J. Chem. Theory Comput. 2010 Apr 14;6(5):1509–19. 40. Grant BJ, Lars Skjærven, Yao X. The Bio3D packages for structural bioinformatics. 2020 Aug 17;30(1):20–30 41. David CC, Jacobs DJ. Principal Component Analysis: A Method for Determining the Essential Dynamics of Proteins. Protein Dynamics. 2013 Sep 3;193–226.